ArticleEuropean journal of nuclear medicine and molecular imaging2026
Stratifying risk of heart failure death and arrhythmic events: a ¹²³I-meta-iodobenzylguanidine-based multinomial logistic model.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting Sudden Cardiac Death in Heart Failure with Mildly Reduced/Preserved Left Ventricular Ejection Fraction: A Clinical Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDifferentiating heart failure-related death (HFD) from arrhythmic events (ArEs) is clinically important for patients with chronic heart failure (CHF), as they have distinct mechanisms and therapeutic strategies. We developed and validated a multivariable model to predict HFD, ArEs, and survival using clinical parameters and cardiac
methodsWe retrospectively analyzed data derived from 997 patients with CHF (mean age 70 ± 13 years, left ventricular ejection fraction (LVEF) 32% ± 13%) over a mean follow-up of 41 ± 27 months. Outcomes were survival, HFD, or ArEs (including sudden cardiac death). Appropriate implantable cardioverter defibrillator therapy for lethal arrhythmias was included in ArEs. Late heart-to-mediastinum ratios (HMRs) were derived from
resultsSelected variables were age, sex, New York Heart Association (NYHA) functional class, LVEF, hemoglobin, estimated glomerular filtration rate, hypertension, ventricular tachycardia history, and late
conclusionsA practical, interpretable model incorporating clinical and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.